Effect of progesterone receptor status on efficacy of aromatase inhibitors and survival time in patients with advanced breast cancer
To investigate the effect of progesterone receptor (PR) on the efficacy of first-line aromatase inhibitor (AI) endocrine therapy and progression-free survival (PFS) in patients with estrogen receptor (ER) positive HER-2 negative advanced breast cancer. The clinical data of 198 patients with advanced...
Gespeichert in:
| Veröffentlicht in: | Zhong hua yi xue za zhi 2022-03, Vol.102 (10), p.741-744 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | chi |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 744 |
|---|---|
| container_issue | 10 |
| container_start_page | 741 |
| container_title | Zhong hua yi xue za zhi |
| container_volume | 102 |
| creator | Zhang, M W Lyu, H M Niu, L M Zeng, H A Yan, M |
| description | To investigate the effect of progesterone receptor (PR) on the efficacy of first-line aromatase inhibitor (AI) endocrine therapy and progression-free survival (PFS) in patients with estrogen receptor (ER) positive HER-2 negative advanced breast cancer. The clinical data of 198 patients with advanced breast cancer treated in Henan Cancer Hospital from January 2014 to October 2019 were collected. The Chi-square test was used to compare the difference between the two groups, and the Cox regression model was used to analyze the related prognostic factors. The median progression-free survival time ((PFS)) of PR+and PR- patients were 12.5 months and 9.0 months, respectively, and the difference was statistically significant (
=0.004). The clinical benefit rate (CBR) was 81.1% and 63.1%, respectively, and the difference was not statistically significant ( |
| doi_str_mv | 10.3760/cma.j.cn112137-20210708-01531 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2638953321</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2638953321</sourcerecordid><originalsourceid>FETCH-LOGICAL-p569-3dfd3731302e578ba1214ac9369ce910fbdccbfa539d752b7e2b2b4b68a23abe3</originalsourceid><addsrcrecordid>eNo1kEtLAzEUhbNQbKn9C5KN4GZqktt5ZCmlPqDgpvtyk7mxkc7DJFPp3h_uFOvqcDkfF77D2L0UCygL8WgbXHwubCulklBmSigpSlFlQuYgr9hUjFSmllpO2DxGb8SyBH2mbtgEclUJIfWU_aydI5t453gfug-KiULXEg9kqU9d4DFhGiLvWk7OeYv2dGYxdA0mjMR9u_fGj2Tk2NY8DuHoj3jgyTfnkveYPLUp8m-f9hzrI7aWam4CYUzcnq9wy64dHiLNLzlj2-f1dvWabd5f3lZPm6zPC51B7WooQYJQlJeVwVF8iVZDoS1pKZyprTUOc9B1mStTkjLKLE1RoQI0BDP28Pd2NP0aRtVd46OlwwFb6oa4UwVUOgcY95yxuws6mIbqXR98g-G0-x8OfgGrw3Wi</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2638953321</pqid></control><display><type>article</type><title>Effect of progesterone receptor status on efficacy of aromatase inhibitors and survival time in patients with advanced breast cancer</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Zhang, M W ; Lyu, H M ; Niu, L M ; Zeng, H A ; Yan, M</creator><creatorcontrib>Zhang, M W ; Lyu, H M ; Niu, L M ; Zeng, H A ; Yan, M</creatorcontrib><description>To investigate the effect of progesterone receptor (PR) on the efficacy of first-line aromatase inhibitor (AI) endocrine therapy and progression-free survival (PFS) in patients with estrogen receptor (ER) positive HER-2 negative advanced breast cancer. The clinical data of 198 patients with advanced breast cancer treated in Henan Cancer Hospital from January 2014 to October 2019 were collected. The Chi-square test was used to compare the difference between the two groups, and the Cox regression model was used to analyze the related prognostic factors. The median progression-free survival time ((PFS)) of PR+and PR- patients were 12.5 months and 9.0 months, respectively, and the difference was statistically significant (
=0.004). The clinical benefit rate (CBR) was 81.1% and 63.1%, respectively, and the difference was not statistically significant (
<0.001). PR is an independent prognostic factor of first-line AI endocrine therapy in ER-positive HER-2-negative patients. PR+type breast cancer has a better respon</description><identifier>ISSN: 0376-2491</identifier><identifier>DOI: 10.3760/cma.j.cn112137-20210708-01531</identifier><identifier>PMID: 35280019</identifier><language>chi</language><publisher>China</publisher><subject>Aromatase Inhibitors - therapeutic use ; Breast Neoplasms - drug therapy ; Female ; Humans ; Receptors, Progesterone - metabolism ; Survival Rate</subject><ispartof>Zhong hua yi xue za zhi, 2022-03, Vol.102 (10), p.741-744</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35280019$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, M W</creatorcontrib><creatorcontrib>Lyu, H M</creatorcontrib><creatorcontrib>Niu, L M</creatorcontrib><creatorcontrib>Zeng, H A</creatorcontrib><creatorcontrib>Yan, M</creatorcontrib><title>Effect of progesterone receptor status on efficacy of aromatase inhibitors and survival time in patients with advanced breast cancer</title><title>Zhong hua yi xue za zhi</title><addtitle>Zhonghua Yi Xue Za Zhi</addtitle><description>To investigate the effect of progesterone receptor (PR) on the efficacy of first-line aromatase inhibitor (AI) endocrine therapy and progression-free survival (PFS) in patients with estrogen receptor (ER) positive HER-2 negative advanced breast cancer. The clinical data of 198 patients with advanced breast cancer treated in Henan Cancer Hospital from January 2014 to October 2019 were collected. The Chi-square test was used to compare the difference between the two groups, and the Cox regression model was used to analyze the related prognostic factors. The median progression-free survival time ((PFS)) of PR+and PR- patients were 12.5 months and 9.0 months, respectively, and the difference was statistically significant (
=0.004). The clinical benefit rate (CBR) was 81.1% and 63.1%, respectively, and the difference was not statistically significant (
<0.001). PR is an independent prognostic factor of first-line AI endocrine therapy in ER-positive HER-2-negative patients. PR+type breast cancer has a better respon</description><subject>Aromatase Inhibitors - therapeutic use</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Receptors, Progesterone - metabolism</subject><subject>Survival Rate</subject><issn>0376-2491</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kEtLAzEUhbNQbKn9C5KN4GZqktt5ZCmlPqDgpvtyk7mxkc7DJFPp3h_uFOvqcDkfF77D2L0UCygL8WgbXHwubCulklBmSigpSlFlQuYgr9hUjFSmllpO2DxGb8SyBH2mbtgEclUJIfWU_aydI5t453gfug-KiULXEg9kqU9d4DFhGiLvWk7OeYv2dGYxdA0mjMR9u_fGj2Tk2NY8DuHoj3jgyTfnkveYPLUp8m-f9hzrI7aWam4CYUzcnq9wy64dHiLNLzlj2-f1dvWabd5f3lZPm6zPC51B7WooQYJQlJeVwVF8iVZDoS1pKZyprTUOc9B1mStTkjLKLE1RoQI0BDP28Pd2NP0aRtVd46OlwwFb6oa4UwVUOgcY95yxuws6mIbqXR98g-G0-x8OfgGrw3Wi</recordid><startdate>20220315</startdate><enddate>20220315</enddate><creator>Zhang, M W</creator><creator>Lyu, H M</creator><creator>Niu, L M</creator><creator>Zeng, H A</creator><creator>Yan, M</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20220315</creationdate><title>Effect of progesterone receptor status on efficacy of aromatase inhibitors and survival time in patients with advanced breast cancer</title><author>Zhang, M W ; Lyu, H M ; Niu, L M ; Zeng, H A ; Yan, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p569-3dfd3731302e578ba1214ac9369ce910fbdccbfa539d752b7e2b2b4b68a23abe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>chi</language><creationdate>2022</creationdate><topic>Aromatase Inhibitors - therapeutic use</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Receptors, Progesterone - metabolism</topic><topic>Survival Rate</topic><toplevel>online_resources</toplevel><creatorcontrib>Zhang, M W</creatorcontrib><creatorcontrib>Lyu, H M</creatorcontrib><creatorcontrib>Niu, L M</creatorcontrib><creatorcontrib>Zeng, H A</creatorcontrib><creatorcontrib>Yan, M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Zhong hua yi xue za zhi</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, M W</au><au>Lyu, H M</au><au>Niu, L M</au><au>Zeng, H A</au><au>Yan, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of progesterone receptor status on efficacy of aromatase inhibitors and survival time in patients with advanced breast cancer</atitle><jtitle>Zhong hua yi xue za zhi</jtitle><addtitle>Zhonghua Yi Xue Za Zhi</addtitle><date>2022-03-15</date><risdate>2022</risdate><volume>102</volume><issue>10</issue><spage>741</spage><epage>744</epage><pages>741-744</pages><issn>0376-2491</issn><abstract>To investigate the effect of progesterone receptor (PR) on the efficacy of first-line aromatase inhibitor (AI) endocrine therapy and progression-free survival (PFS) in patients with estrogen receptor (ER) positive HER-2 negative advanced breast cancer. The clinical data of 198 patients with advanced breast cancer treated in Henan Cancer Hospital from January 2014 to October 2019 were collected. The Chi-square test was used to compare the difference between the two groups, and the Cox regression model was used to analyze the related prognostic factors. The median progression-free survival time ((PFS)) of PR+and PR- patients were 12.5 months and 9.0 months, respectively, and the difference was statistically significant (
=0.004). The clinical benefit rate (CBR) was 81.1% and 63.1%, respectively, and the difference was not statistically significant (
<0.001). PR is an independent prognostic factor of first-line AI endocrine therapy in ER-positive HER-2-negative patients. PR+type breast cancer has a better respon</abstract><cop>China</cop><pmid>35280019</pmid><doi>10.3760/cma.j.cn112137-20210708-01531</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0376-2491 |
| ispartof | Zhong hua yi xue za zhi, 2022-03, Vol.102 (10), p.741-744 |
| issn | 0376-2491 |
| language | chi |
| recordid | cdi_proquest_miscellaneous_2638953321 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Aromatase Inhibitors - therapeutic use Breast Neoplasms - drug therapy Female Humans Receptors, Progesterone - metabolism Survival Rate |
| title | Effect of progesterone receptor status on efficacy of aromatase inhibitors and survival time in patients with advanced breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T00%3A59%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20progesterone%20receptor%20status%20on%20efficacy%20of%20aromatase%20inhibitors%20and%20survival%20time%20in%20patients%20with%20advanced%20breast%20cancer&rft.jtitle=Zhong%20hua%20yi%20xue%20za%20zhi&rft.au=Zhang,%20M%20W&rft.date=2022-03-15&rft.volume=102&rft.issue=10&rft.spage=741&rft.epage=744&rft.pages=741-744&rft.issn=0376-2491&rft_id=info:doi/10.3760/cma.j.cn112137-20210708-01531&rft_dat=%3Cproquest_pubme%3E2638953321%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2638953321&rft_id=info:pmid/35280019&rfr_iscdi=true |